Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference

Rhea-AI Summary

Bausch Health Companies (NYSE:BHC) announced the presentation of eleven posters at the Fall Clinical Dermatology Conference from October 20-23, 2022, in Las Vegas. The posters will cover new analyses related to ARAZLO (tazarotene) Lotion, DUOBRII (halobetasol propionate and tazarotene) Lotion, and the investigational IDP-126 Gel. Additionally, the presentation includes adaptations on SILIQ (brodalumab) Injection and five encore presentations, showcasing advancements in dermatological treatments. This reflects the company’s commitment to research and patient safety.

Eleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126 Gel

LAVAL, QC / ACCESSWIRE / October 20, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev. The presentations will feature new data around ARAZLO® (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, and the investigational medicine IDP-126 Gel-a combination retinoid, antibacterial and antibiotic topical. Two other presentations are adaptations featuring research on SILIQ® (brodalumab) Injection, 210 mg/1.5 mL. Please see below for warning about suicidal ideation and behavior with SILIQ. There will also be five encore presentations, including a systemic review of onychomycosis dermatophytoma treatment.

"Ortho Dermatologics remains committed to research to ensure the safety and efficacy of our portfolio with patients top of mind," said Richard Lajoie, vice president and general manager, Ortho Dermatologics. "At this year's Fall Clinical Dermatology Conference, we look forward to the opportunity to personally connect with dermatologists to share new data on our investigational acne medicine, IDP-126 Gel, as well as new analyses on two of our prominent acne and psoriasis medications, ARAZLO® and DUOBRII®."

The complete list of Ortho Dermatologics' poster presentations is as follows:

ARAZLO® (tazarotene) Lotion, 0.045%

• "Impact of Seasonal Variation on the Efficacy and Safety of Tazarotene 0.045% Lotion for Acne: Post Hoc Analysis of Pooled Phase 3 Data." Draelos et al.
• "Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability." Kircik et al.

DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%

• "Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action." Kircik et al.
• "Efficacy and Safety of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis from Real-World Patient Perspectives" Lain et al.
• "Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Decreases TNF-α Levels Within Psoriatic Lesions." Draelos et al.

IDP-126 Gel (Investigational Drug)

• "Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat." Feldman et al.
• "Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Mesh Gel in Pediatric Participants." Eichenfield et al.

SILIQ® (brodalumab) Injection, 210 mg/1.5 mL

• "Unique Mechanism of Action of Brodalumab May Correlate With Efficacy vs Ustekinumab." Armstrong et al.
• "Inhibition of Interleukin-17 Cytokines With Brodalumab May Correlate With Efficacy in Patients With Psoriasis and Prior Biologic Exposure." Lain et al.
• "Brodalumab: 4-Year US Pharmacovigilance Report." Lebwohl et al.

JUBLIA® (efinaconazole) Topical Solution, 10%

• "Onychomycosis Dermatophytoma Treatment: A Systematic Review of the Literature." Lipner et al.

Important Safety Information for ARAZLO® (tazarotene) Lotion, 0.045%

What is ARAZLO?

ARAZLO^® (tazarotene) Lotion, 0.045% is a prescription medicine used on the skin (topical) to treat people 9 years of age and older with acne, which can include blackheads, whiteheads, and other pimples.

It is not known if ARAZLO is safe and effective in children under 9 years of age.

Important Safety Information

ARAZLO is for use on skin only. Do not use ARAZLO in your eyes, mouth, the corners of your nose, or vagina.

What is the most important information I should know about ARAZLO?

• ARAZLO may cause birth defects if used during pregnancy.
• You must not be pregnant when you start using ARAZLO or become pregnant during treatment.
• Use effective birth control during treatment.
• Stop using ARAZLO and tell your healthcare provider right away if you become pregnant during treatment.

Before using ARAZLO, tell your healthcare provider about all your medical conditions, including if you:

• have eczema or any other skin problems.
• are breastfeeding or plan to breastfeed. If you use ARAZLO while breastfeeding, use it for the shortest time needed. Do not apply ARAZLO directly to the nipple and surrounding area to avoid exposing your child to the medicine.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines can make your skin more sensitive to sunlight; ask your healthcare provider for a list of medicines if you are not sure.

Especially tell your healthcare provider about other products you use on your skin (such as benzoyl peroxide), including moisturizers, creams, lotions, or products that can dry out your skin.

What should I avoid while using ARAZLO?

• You should avoid sunlamps, tanning beds, and ultraviolet light during treatment with ARAZLO.
• Minimize exposure to sunlight; you could get severe sunburn.

If you have to be in the sunlight or are sensitive to sunlight, use a sunscreen with an SPF (sun protection factor) of 15 or more and wear protective clothing and a wide-brimmed hat to cover the treated areas.

• Avoid using ARAZLO on skin with eczema or sunburned skin because it may cause severe irritation.

ARAZLO may cause side effects, including:

Skin irritation. ARAZLO may cause irritation including skin dryness, pain, redness, excessive flaking or peeling. If you develop these symptoms, your healthcare provider may tell you to use a moisturizer, adjust the dosing, or completely stop treatment with ARAZLO.

These are not all the possible side effects of ARAZLO. Call your doctor for medical advice about side effects. You may report side effects to Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information, including Patient Information.

Important Safety Information for DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%

What is DUOBRII^® Lotion?

DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is a prescription medicine used on the skin (topical) to treat adults with plaque psoriasis. It is not known if DUOBRII Lotion is safe and effective in children.

Important Safety Information

• DUOBRII Lotion is for use on the skin only; do not use it in your mouth, eyes, or vagina.

What is the most important Information I should know about DUOBRII Lotion?

DUOBRII Lotion may cause birth defects if used during pregnancy.

A negative pregnancy test must be obtained before females of child-bearing age start using DUOBRII Lotion and they must use effective birth control during treatment. Begin treatment during a normal menstrual period.

Stop using DUOBRII Lotion and tell your healthcare provider right away if you become pregnant while using DUOBRII Lotion.

Before you use DUOBRII Lotion, tell your healthcare provider if you:

• have eczema or any other skin problems, including skin infections, which may need to be treated before using DUOBRII.
• have diabetes, adrenal gland problems or liver problems.
• are breastfeeding or plan to breastfeed. If you use DUOBRII and breastfeed, do not apply DUOBRII to your nipple area.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

• Especially tell your healthcare provider if you take corticosteroids by mouth or injection or use other skin products that contain corticosteroids.
• Ask your healthcare provider for a list of medicines that may make your skin more sensitive to sunlight.

What should I avoid during treatment with DUOBRII?

• To avoid a severe sunburn, avoid sunlight, including sunlamps and tanning beds, as much as possible, and use sunscreen, protective clothing and a hat while in sunlight. Talk to your healthcare provider if you get sunburn, and do not use DUOBRII Lotion until your sunburn is healed.
• Avoid using DUOBRII on skin with eczema because it may cause severe irritation.

DUOBRII may cause side effects, including:

• If too much DUOBRII passes through your skin it can cause adrenal glands to stop working
• Cushing's syndrome, a condition from too much exposure to the hormone cortisol
• High blood sugar (hyperglycemia)
• Effects of growth and weight in children
• Skin irritation. If you get too much skin irritation at the site of application, your healthcare provider may tell you to interrupt or stop using DUOBRII or to use it less often.
• Vision problems, including an increased chance of developing cataracts and glaucoma. Tell your healthcare provider about any vision problems during treatment.

The most common side effects of DUOBRII Lotion include: redness, itching, swelling, burning, stinging, application site pain, inflamed hair follicles (folliculitis), thinning of the skin (atrophy), peeling and rash.

To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

This is not all of the Important Safety Information you need to know about DUOBRII; please click here for full Prescribing Information, including Patient Information.

Important Safety Information for SILIQ® (brodalumab) Injection, 210 mg/1.5 mL

What is SILIQ?

SILIQ® injection is a prescription medicine used to treat adults with moderate to severe plaque psoriasis:

• who may benefit from injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light treatment) and
• who have tried another systemic therapy that didn't work or stopped working

It is not known if SILIQ is safe and effective in children.

What is the most important information I should know about SILIQ?

Suicidal thoughts or behavior: Some patients taking SILIQ have had suicidal thoughts or ended their own lives. This risk is higher if you have a history of suicidal thoughts or depression. It is not known if SILIQ causes these thoughts or actions. Get medical help right away if you or a family member notices that you have any of the following symptoms:

• new or worsening depression, anxiety, or mood problems
• thoughts of suicide, dying, or hurting yourself
• attempt to commit suicide, or acting on dangerous impulses
• other unusual changes in your behavior or mood

Your healthcare provider will give you a SILIQ patient/wallet card about symptoms that need medical attention right away. Carry the card with you during treatment with SILIQ and show it to all of your healthcare providers.

Serious Infections: SILIQ may lower the ability of your immune system to fight infections and may increase your risk of infections:

• Your healthcare provider should check you for tuberculosis (TB) before starting treatment with SILIQ and may treat you for TB before starting SILIQ if you have TB or a history of it
• You and your healthcare provider need to watch closely for signs and symptoms of infection during treatment with SILIQ, including fever, sweats, chills, shortness of breath, stomach issues, muscle aches, cough, sore throat or trouble swallowing, warm/red/painful skin sores, burning while urinating or more frequent urination

Who should not use SILIQ?

Do not use SILIQ if you have Crohn's disease. Tell your healthcare provider if you develop diarrhea, bloody stools, stomach pain or cramping, sudden or uncontrollable bowel movements, loss of appetite, constipation, weight loss, fever or tiredness as these may be symptoms of Crohn's disease.

Before starting SILIQ, tell your healthcare provider if you:

• have a history of mental health problems, including suicidal thoughts, depression, anxiety, or mood problems
• have an infection that does not go away or keeps coming back
• have TB or have been in close contact with someone with TB
• have recently received or are scheduled to receive an immunization (vaccine). You should avoid getting live vaccines while being treated with SILIQ
• are or plan to become pregnant, or are breastfeeding or plan to do so. It is unknown if SILIQ can harm your unborn or newborn baby

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use SILIQ?

See the detailed "Instructions for Use" that come with your SILIQ for information on the right way to store, prepare, and give your SILIQ injections at home, and how to properly throw away (dispose of) used SILIQ prefilled syringes. Use SILIQ exactly as your healthcare provider tells you to use it.

What are possible side effects of SILIQ?

SILIQ may cause serious side effects. See "What is the most important information I should know about SILIQ?" and "Who should not take SILIQ?"

The most common side effects of SILIQ include:

Joint pain Muscle pain

Headache Injection site reactions

Tiredness Flu

Diarrhea Low white blood cell count (neutropenia)

Mouth or throat pain Fungal infections of the skin

Nausea

Call your doctor for medical advice on side effects. You are encouraged to report negative side effects of prescription drugs to Bausch Health at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for accompanying full Prescribing Information, including Boxed Warning about suicidal ideation and behavior, and Medication Guide.

Important Safety Information for JUBLIA® (efinaconazole) Topical Solution, 10%

INDICATION

JUBLIA (efinaconazole) Topical Solution, 10% is a prescription medicine used to treat fungal infections of the toenails.

IMPORTANT SAFETY INFORMATION

• JUBLIA is for use on nails and surrounding skin only. Do not use JUBLIA in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor.
• The safety and efficacy of JUBLIA have not been established in children under six years old.
• Before you use JUBLIA, tell your doctor about all your medical conditions, including if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed, because it is not known whether JUBLIA can harm an unborn fetus or nursing infant.
• Tell your doctor about all medications you are taking, and whether you have any other nail infections.
• JUBLIA is flammable. Avoid heat and flame while applying JUBLIA to your toenail.
• JUBLIA may cause irritation at the treated site. The most common side effects include: ingrown toenail, redness, itching, swelling, burning or stinging, blisters, and pain. Tell your doctor about any side effects that bother you or do not go away.

To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information, including Patient Information.

Visit www.JubliaRx.com to learn more.

About Ortho Dermatologics
Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis,onychomycosis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

ARAZLO, DUOBRII, SILIQ, and JUBLIA are trademarks of Ortho Dermatologics' affiliated entities.
Ortho Dermatologics is a trademark of Ortho Dermatologics' affiliated entities.

© 2022 Ortho Dermatologics' affiliated entities.
ORD.0136.USA.22

Bausch Health Investor Contact: Christina Cheng ir@bauschhealth.com

Bausch Health Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com

SOURCE: Bausch Health Companies Inc.

View source version on accesswire.com:
https://www.accesswire.com/721164/Ortho-Dermatologics-To-Present-New-Data-at-the-2022-Fall-Clinical-Dermatology-Conference

FAQ

What new data is Bausch Health presenting at the Fall Clinical Dermatology Conference 2022?

Bausch Health is presenting new analyses related to ARAZLO, DUOBRII, and the investigational IDP-126 Gel.

When is the Fall Clinical Dermatology Conference taking place?

The Fall Clinical Dermatology Conference is occurring from October 20-23, 2022.

What is ARAZLO and what is it used for?

ARAZLO (tazarotene) Lotion, 0.045%, is a prescription treatment used for acne in individuals aged 9 years and older.

What type of presentations will Bausch Health feature at the conference?

Bausch Health will feature eleven poster presentations and five encore presentations focusing on various dermatological treatments.

What is the significance of the IDP-126 Gel presentation at the conference?

The IDP-126 Gel presentation is significant as it showcases an investigational acne medicine and highlights Bausch Health's commitment to advancing dermatological care.